TC Biopharm () (TCBP)
TC Biopharm () Statistics
Share Statistics
TC Biopharm () has 512.99K shares outstanding. The number of shares has increased by 156.91% in one year.
| Shares Outstanding | 512.99K |
| Shares Change (YoY) | 156.91% |
| Shares Change (QoQ) | 1554.19% |
| Owned by Institutions (%) | 0.22% |
| Shares Floating | 2.47K |
| Failed to Deliver (FTD) Shares | 5.83K |
| FTD / Avg. Volume | 1.54% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -41.71 and the forward PE ratio is null. TC Biopharm ()'s PEG ratio is 0.83.
| PE Ratio | -41.71 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 91.76 |
| P/FCF Ratio | -23.12 |
| PEG Ratio | 0.83 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TC Biopharm ().
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.2, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.2 |
| Quick Ratio | 1.2 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.17 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-144.07K |
| Employee Count | 41 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.09M |
| Effective Tax Rate | 15.56% |
Stock Price Statistics
The stock price has increased by -99.8% in the last 52 weeks. The beta is 0.01, so TC Biopharm ()'s price volatility has been higher than the market average.
| Beta | 0.01 |
| 52-Week Price Change | -99.8% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 43.03 |
| Relative Strength Index (RSI) | 39.17 |
| Average Volume (20 Days) | 377.72K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -14.24M |
| Net Income | -5.91M |
| EBITDA | -13.61M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
The company has 2.46M in cash and 1.8M in debt, giving a net cash position of 661.45K.
| Cash & Cash Equivalents | 2.46M |
| Total Debt | 1.8M |
| Net Cash | 661.45K |
| Retained Earnings | -38.84M |
| Total Assets | 6.87M |
| Working Capital | 423.86K |
Cash Flow
In the last 12 months, operating cash flow was -10.54M and capital expenditures -110.35K, giving a free cash flow of -10.66M.
| Operating Cash Flow | -10.54M |
| Capital Expenditures | -110.35K |
| Free Cash Flow | -10.66M |
| FCF Per Share | -0.09 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCBP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TCBP is $48, which is 9500% higher than the current price. The consensus rating is "Buy".
| Price Target | $48 |
| Price Target Difference | 9500% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Feb 10, 2025. It was a backward split with a ratio of 1:20.
| Last Split Date | Feb 10, 2025 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -14.71 |
| Piotroski F-Score | 2 |